These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 9641560

  • 1. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset.
    Harries MH, Samson NA, Cilia J, Hunter AJ.
    Br J Pharmacol; 1998 May; 124(2):409-15. PubMed ID: 9641560
    [Abstract] [Full Text] [Related]

  • 2. Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.
    Hatcher JP, Loudon JM, Hagan JJ, Clark MS.
    Psychopharmacology (Berl); 1998 Aug; 138(3-4):275-82. PubMed ID: 9725749
    [Abstract] [Full Text] [Related]

  • 3. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW, Cohen ML.
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [Abstract] [Full Text] [Related]

  • 4. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, Riley GJ, Noy G, Orlek BS.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
    [Abstract] [Full Text] [Related]

  • 5. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
    Bromidge SM, Brown F, Cassidy F, Clark MS, Dabbs S, Hadley MS, Hawkins J, Loudon JM, Naylor CB, Orlek BS, Riley GJ.
    J Med Chem; 1997 Dec 19; 40(26):4265-80. PubMed ID: 9435896
    [Abstract] [Full Text] [Related]

  • 6. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
    Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, Sapir M, Levy A, Heldman E.
    J Pharmacol Exp Ther; 1991 Apr 19; 257(1):392-403. PubMed ID: 2019998
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine.
    Terry AV, Buccafusco JJ, Borsini F, Leusch A.
    Psychopharmacology (Berl); 2002 Jul 19; 162(3):292-300. PubMed ID: 12122487
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Progress in medicinal chemistry of novel selective muscarinic agonists.
    Fisher A, Karton Y, Heldman E, Gurwitz D, Haring R, Meshulam H, Brandeis R, Pittel Z, Segall Y, Marciano D.
    Drug Des Discov; 1993 Jul 19; 9(3-4):221-35. PubMed ID: 8400004
    [Abstract] [Full Text] [Related]

  • 12. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
    McArthur RA, Gray J, Schreiber R.
    Curr Opin Investig Drugs; 2010 Jul 19; 11(7):740-60. PubMed ID: 20571970
    [Abstract] [Full Text] [Related]

  • 13. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
    Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN.
    Br J Pharmacol; 1999 Apr 19; 126(7):1620-4. PubMed ID: 10323594
    [Abstract] [Full Text] [Related]

  • 14. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
    Vamvakidès A.
    Ann Pharm Fr; 2003 May 19; 61(3):207-10. PubMed ID: 12714934
    [Abstract] [Full Text] [Related]

  • 15. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
    Ladner CJ, Lee JM.
    Exp Neurol; 1999 Aug 19; 158(2):451-8. PubMed ID: 10415152
    [Abstract] [Full Text] [Related]

  • 16. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN, Malviya M, Sadashiva CT, Subhash MN, Rangappa KS.
    Neurochem Int; 2008 Feb 19; 52(3):376-83. PubMed ID: 17719699
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates.
    Rupniak NM, Tye SJ, Iversen SD.
    J Neurol Sci; 1992 Jul 19; 110(1-2):222-7. PubMed ID: 1506863
    [Abstract] [Full Text] [Related]

  • 18. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
    Züchner T, Perez-Polo JR, Schliebs R.
    J Neurosci Res; 2004 Jul 15; 77(2):250-7. PubMed ID: 15211591
    [Abstract] [Full Text] [Related]

  • 19. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
    Fisher A.
    Neurodegener Dis; 2008 Jul 15; 5(3-4):237-40. PubMed ID: 18322400
    [Abstract] [Full Text] [Related]

  • 20. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS.
    J Mol Neurosci; 2002 Jul 15; 19(1-2):187-93. PubMed ID: 12212779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.